Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort
M. Lukasiewicz(Délégation Paris 5), Mauricio Tohen(University of New Mexico), Adeline Besnard(Eli Lilly (United States)), Bruno Falissard(Inserm), Catherine Reed(Eli Lilly (United States)), Stéphanie Gerard(Eli Lilly (United States)), Jean‐Michel Azorin(Hôpital Sainte-Marguerite), Hélène Sapin(Eli Lilly (United States)), Eléna Perrin(Eli Lilly (United States))
Cited by 127
Related Papers
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
|American Journal of Psychiatry|2013|754
Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial
|The Lancet|2011|674
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders
|Bipolar Disorders|2009|507
Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP)
|Journal of Affective Disorders|1998|434
Complicated grief after death of a relative in the intensive care unit
|European Respiratory Journal|2015|359